Predicta Biosciences

Predicta Biosciences, founded by leading cancer genomics researchers and clinicians, is a precision oncology company developing novel diagnostic and therapeutic products. The company's non-invasive diagnostics initially focus on multiple myeloma, evaluating patients' immune system cells to provide doctors with a unique ability to determine the likelihood of a patient responding to immunotherapy. Leveraging extensive genomic and transcriptomic patient data, Predicta is also building a one-of-a-kind clinical database for identifying new therapeutic targets.